ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01283945
Recruitment Status : Completed
First Posted : January 26, 2011
Last Update Posted : April 12, 2018
Sponsor:
Information provided by (Responsible Party):
Servier

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 2016
  Actual Study Completion Date : May 4, 2017